mug190 Antibody

What is MUC-19 antibody and what biological systems is it primarily used for?

MUC-19 antibody is a research tool designed to detect MUC-19, a member of the Mucin family of gel-forming glycoproteins. MUC-19 is expressed in various tissues including corneal epithelial cells, conjunctival goblet cells, lacrimal gland cells, submandibular gland mucous cells, and submucosal gland cells of the trachea. Notably, MUC-19 expression is reduced in patients with Sjögren's syndrome, making the antibody valuable for studying this condition . Additionally, MUC-19 is upregulated in epithelial cells during inflammatory responses when exposed to cytokines including TNF-alpha, IL-1 beta, IL-5, and IL-8, particularly in middle ear models . Research applications for this antibody are predominantly focused on immunohistochemistry of tissues expressing mucins and investigating mucin-related pathologies.

How should I store and handle MUC-19 antibody to maintain optimal performance?

For optimal performance, MUC-19 antibody should be stored following specific guidelines to preserve activity and specificity. Use a manual defrost freezer and avoid repeated freeze-thaw cycles, which can degrade antibody performance. The antibody maintains stability for 12 months from the date of receipt when stored at -20 to -70°C in unopened containers . After opening, the antibody remains stable for approximately 1 month when stored at 2 to 8°C under sterile conditions, or for 6 months at -20 to -70°C under sterile conditions . When preparing working solutions, use sterile technique and only reconstitute the amount needed for immediate experiments. Reconstitution calculators available from suppliers can help determine precise dilution requirements for your specific experimental setup.

What initial validation steps should I perform when receiving a new lot of MUC-19 antibody?

Initial validation is critical when working with a new antibody lot. Begin with application-specific positive and negative controls to verify antibody performance. For MUC-19 antibody, human salivary gland tissue serves as an excellent positive control for immunohistochemistry applications, as MUC-19 shows specific localization to mucosal cells in this tissue . A systematic validation approach should include:

• Antibody titration to determine optimal working concentration

• Verification of staining patterns against known expression profiles

• Cross-reactivity assessment with related proteins

• Comparison with previous lots using standardized samples

This stepwise strategy aligns with recommendations from the European Monoclonal Antibody Network for proper antibody validation, ensuring reagents are fit for their intended purpose .

What are the recommended protocols for using MUC-19 antibody in immunohistochemistry?

For immunohistochemistry applications with MUC-19 antibody, follow this optimized protocol based on validated methods:

• Fix tissue samples in 10% neutral buffered formalin and embed in paraffin.

• Section tissues at 4-6 μm thickness and mount on positively charged slides.

• Deparaffinize sections through xylene and rehydrate through graded alcohols.

• Perform heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0).

• Block endogenous peroxidase activity with 3% hydrogen peroxide.

• Apply protein block to reduce non-specific binding.

• Incubate with MUC-19 antibody at 15 μg/mL overnight at 4°C (this concentration has been validated for human salivary gland tissue) .

• Detect using appropriate secondary detection system, such as HRP-DAB (brown) visualization.

• Counterstain with hematoxylin, dehydrate, and mount.

This protocol has been demonstrated to produce specific staining localized to mucosal cells in human salivary gland tissue . Optimize antibody concentration for your specific tissue type and target localization.

How can I design an experiment to measure changes in MUC-19 expression in inflammatory conditions?

To design an experiment measuring MUC-19 expression changes in inflammatory conditions, implement a multifactor experimental design that accounts for various parameters:

• Experimental Design Setup:

  • Use Design of Experiments (DOE) methodology rather than one-factor-at-a-time approaches

  • Include multiple experimental and biological replicates

  • Establish proper controls (positive, negative, and vehicle controls)

• Factor Selection for Inflammatory Models:

  • Cytokine treatments (TNF-alpha, IL-1 beta, IL-5, IL-8)

  • Treatment duration (short-term vs. chronic exposure)

  • Dosage levels (minimum 3 concentrations)

  • Cell/tissue type (relevant to research question)

• Response Measurements:

  • Protein expression (Western blot, immunohistochemistry)

  • mRNA expression (qRT-PCR)

  • Functional outcomes (mucin secretion, cell morphology)

• Data Analysis:

  • Statistical methods for multifactor analysis (ANOVA with post-hoc tests)

  • Dose-response curves to determine EC50/EC90 values

  • Fold-change calculations relative to controls

This design allows for comprehensive mapping of how inflammatory conditions modulate MUC-19 expression, while avoiding the significantly longer timeframes required by traditional one-factor-at-a-time methods. Studies using DOE have demonstrated completion in a fraction of the time (weeks versus 6+ months) with statistically robust results .

What controls should I include when using MUC-19 antibody in Western blotting applications?

When using MUC-19 antibody for Western blotting, include these essential controls:

• Positive control: Lysate from tissues known to express MUC-19 (salivary gland, corneal epithelium, or conjunctival tissue)

• Negative control:

  • Lysate from tissues not expressing MUC-19

  • Primary antibody omission control

  • Isotype control antibody at the same concentration

• Molecular weight markers:

  • Pre-stained protein ladders spanning the expected molecular weight range of MUC-19

• Loading control:

  • Housekeeping protein detection (β-actin, GAPDH, etc.)

  • Total protein staining (Ponceau S, SYPRO Ruby)

• Validation controls:

  • Antibody pre-absorption with recombinant antigen

  • Lysates from cell lines with MUC-19 knockdown/knockout

This comprehensive control strategy helps validate specificity and ensures experimental reliability, addressing the European Monoclonal Antibody Network's recommendation that researchers take responsibility for ensuring antibodies are fit for purpose .

How can I optimize MUC-19 antibody purification processes for improved sensitivity?

Optimizing MUC-19 antibody purification requires a systematic approach using Design of Experiments (DOE) methodology. This statistical approach allows for multifactor testing and generates more comprehensive results compared to traditional one-factor-at-a-time methods:

• Experimental Design Framework:

  • Create a custom-designed experiment (25-30 runs) using statistical software like Design-Expert®

  • Focus on detecting main effects and two-factor interactions

  • Test 4-5 key purification factors at 2-3 levels each

• Critical Factors to Investigate:

  Factor	Levels to Test	Purpose
  Process step sequence	Pre vs. Post Protein A	Determine optimal column order
  Residence time	3 different duration levels	Find optimal exposure time
  Buffer pH	3 pH values	Optimize elution conditions
  Salt concentration	2-3 concentration levels	Enhance selectivity

• Response Variables to Measure:

  • Antibody yield (quantitative)

  • Purity (% of contaminants removed)

  • Biological activity (functional assays)

  • Host cell protein clearance

• Analysis and Optimization:

  • Generate statistical models for each response

  • Create contour plots and response surface models

  • Identify optimal factor settings that maximize desirability

  • Validate optimized conditions with confirmation runs

This approach has demonstrated significant time savings (weeks versus 6+ months) while providing statistically sound, multifactor analysis for optimizing purification processes .

What strategies can I employ to resolve conflicting results between different detection methods using MUC-19 antibody?

When encountering conflicting results between detection methods using MUC-19 antibody, implement this systematic troubleshooting approach:

• Comprehensive Method Validation:

  • Validate each detection method independently with appropriate controls

  • Perform side-by-side comparisons using standardized samples

  • Document all experimental parameters meticulously

• Technical Considerations:

  • Evaluate epitope accessibility in different methods (native vs. denatured conditions)

  • Assess whether post-translational modifications affect antibody binding

  • Consider fixation effects on epitope recognition

  • Verify antibody concentration optimization for each method

• Protocol Refinement:

  • Optimize blocking conditions to reduce background

  • Adjust incubation times and temperatures for each method

  • Consider alternative detection systems/amplification methods

• Cross-Validation Strategies:

  • Use orthogonal detection methods (e.g., mass spectrometry)

  • Employ genetic approaches (gene silencing, CRISPR knockout)

  • Validate with alternative antibodies targeting different epitopes

• Statistical Analysis:

  • Calculate 95% confidence intervals for quantitative measurements

  • Compare fold-changes rather than absolute values when appropriate

  • Use appropriate statistical tests to determine significance of differences

By implementing this structured approach, you can systematically identify sources of conflict between methods and develop a cohesive understanding of the true biological state, consistent with recommendations from the European Monoclonal Antibody Network for resolving technical discrepancies .

How can I assess MUC-19 antibody specificity against new variants or isoforms?

To assess MUC-19 antibody specificity against new variants or isoforms, implement this comprehensive validation strategy:

• In Silico Analysis:

  • Perform BLAST searches to identify potential cross-reactive proteins

  • Map the antibody epitope against known MUC-19 isoforms

  • Analyze conservation across species if conducting comparative studies

• Experimental Validation:

  • Test against recombinant proteins of each isoform/variant

  • Measure EC50 and EC90 values against each variant

  • Calculate fold-change in binding affinity relative to reference isoform

  • Generate neutralization curves for each variant

• Controls and Baselines:

  • Establish reference baselines with well-characterized standard samples

  • Include positive controls expressing known isoforms

  • Use negative controls with closely related mucin family members

• Data Visualization and Analysis:

  • Generate dose-response curves rather than simplified heat maps

  • Include 95% confidence intervals for all EC50/EC90 values

  • Compare fold-differences in detection efficiency between variants

  • Examine reproducibility across multiple experimental replicates

• Documentation Standards:

  • Document all validation experiments according to established reporting guidelines

  • Include controls for all experimental variables

  • Report absolute values and relative differences compared to reference standards

What are the most common pitfalls when using MUC-19 antibody, and how can they be addressed?

Common pitfalls when using MUC-19 antibody and their solutions include:

• High Background Signal:

  • Cause: Insufficient blocking, excessive antibody concentration, or non-specific binding

  • Solution: Optimize blocking conditions (test different blocking agents like BSA, normal serum, or commercial blockers); titrate antibody concentration; increase wash duration and frequency; include 0.1-0.3% Triton X-100 in wash buffers for IHC applications

• Weak or No Signal:

  • Cause: Epitope masking, insufficient antigen retrieval, or antibody degradation

  • Solution: Optimize antigen retrieval methods (test multiple buffers and pH conditions); verify antibody storage conditions; test fresh antibody lot; increase antibody concentration or incubation time; switch to more sensitive detection systems

• Non-specific Banding in Western Blots:

  • Cause: Cross-reactivity, protein degradation, or sample overloading

  • Solution: Optimize sample preparation (include protease inhibitors); reduce antibody concentration; increase blocking stringency; verify sample quality with total protein stains

• Inconsistent Results Between Experiments:

  • Cause: Variability in experimental conditions or antibody lot differences

  • Solution: Standardize all protocols; prepare master mixes; include internal controls in each experiment; validate new antibody lots against previous standards

• False Positives in Tissues Not Known to Express MUC-19:

  • Cause: Cross-reactivity with related mucins or non-specific binding

  • Solution: Validate with orthogonal methods (qPCR, RNA-seq); include knockout/knockdown controls; pre-absorb antibody with recombinant protein

These troubleshooting approaches are consistent with the European Monoclonal Antibody Network's guidance for ensuring antibodies are fit for purpose in research applications .

How can I verify MUC-19 antibody performance across different experimental batches?

To verify MUC-19 antibody performance across different experimental batches, implement this quality control system:

• Reference Standards Establishment:

  • Create a standard operating procedure (SOP) for antibody validation

  • Establish a panel of reference samples (positive and negative controls)

  • Document baseline performance metrics (signal intensity, background levels, specificity patterns)

• Batch-to-Batch Validation Protocol:

  • Test each new antibody batch in parallel with the previous validated batch

  • Run standardized positive controls (human salivary gland tissue for IHC)

  • Quantify staining intensity and pattern consistency

  • Measure signal-to-noise ratios across multiple replicates

• Quantitative Assessment Methods:

  • Calculate coefficient of variation (CV) between batches

  • Set acceptability thresholds (typically CV < 15% for quantitative applications)

  • Perform statistical comparisons (t-tests or ANOVA) between batch results

  • Document fold-changes in sensitivity or specificity

• Documentation and Tracking System:

  • Maintain detailed records of each antibody lot (source, lot number, validation date)

  • Create antibody validation reports with images and quantitative data

  • Implement an electronic laboratory information management system (LIMS) if possible

• Corrective Actions for Failed Validation:

  • Adjust working concentration if needed based on titration curves

  • Contact manufacturer with validation data if antibody fails specifications

  • Maintain inventory of validated antibody lots for critical experiments

This systematic approach ensures experimental reproducibility and allows tracking of antibody performance over time, in line with the European Monoclonal Antibody Network's recommendations for antibody validation .

How can I design experiments to investigate MUC-19's role in Sjögren's syndrome?

To investigate MUC-19's role in Sjögren's syndrome, design a comprehensive experimental approach:

• Experimental Design Considerations:

  • Implement a multifactor Design of Experiments (DOE) approach rather than one-factor-at-a-time testing

  • Include appropriate controls and biological replicates

  • Plan for both in vitro and ex vivo components

• Patient Sample Analysis:

  • Compare MUC-19 expression in salivary gland biopsies from Sjögren's patients vs. healthy controls

  • Quantify protein levels using immunohistochemistry with standardized scoring systems

  • Correlate MUC-19 expression with clinical parameters (salivary flow rates, symptom severity)

• Cell Culture Models:

  Experimental Factor	Levels to Test	Measurements
  Inflammatory cytokines	TNF-α, IL-1β, IL-6, IFN-γ	MUC-19 expression (protein/mRNA)
  Exposure duration	Acute (24h), chronic (7 days)	Secretory function, cell viability
  Autoantibody exposure	Patient-derived IgG, control IgG	Cellular response markers
  Therapeutic interventions	Anti-inflammatory compounds	Rescue of MUC-19 expression

• Mechanistic Studies:

  • siRNA knockdown of MUC-19 to assess functional consequences

  • ChIP assays to investigate transcriptional regulation

  • Co-immunoprecipitation to identify protein interaction partners

• Statistical Analysis Plan:

  • Power analysis to determine sample sizes

  • Mixed-effects models for longitudinal data

  • Multiple comparison corrections for hypothesis testing

  • Correlation analyses between molecular and clinical parameters

This comprehensive approach allows for both descriptive and mechanistic insights into MUC-19's role in Sjögren's syndrome pathogenesis, optimizing experimental design through statistical methodologies that have been shown to significantly reduce research timeframes .

What are the methodological considerations when studying MUC-19 in inflammatory airway conditions?

When studying MUC-19 in inflammatory airway conditions, consider these methodological approaches:

• Model Selection and Validation:

  • Choose appropriate in vitro systems (primary human bronchial epithelial cells, air-liquid interface cultures)

  • Select animal models that recapitulate human airway biology

  • Validate MUC-19 expression patterns in model systems compared to human samples

• Inflammatory Stimuli Characterization:

  • Test physiologically relevant cytokines (TNF-alpha, IL-1 beta, IL-5, IL-8)

  • Include pathogen-associated molecular patterns (PAMPs) as stimuli

  • Design time-course experiments to distinguish acute vs. chronic responses

  • Quantify dose-responses with EC50/EC90 measurements

• Technical Considerations for Airway Samples:

  • Optimize tissue fixation for mucin preservation (avoid overfixation)

  • Develop specialized extraction protocols for highly glycosylated proteins

  • Consider decellularized airway matrices for 3D culture systems

  • Implement specialized staining techniques for mucin visualization

• Outcome Measurements:

  • Quantify MUC-19 expression at protein and mRNA levels

  • Assess mucin secretion rates and viscosity

  • Evaluate mucociliary clearance in functional models

  • Monitor epithelial barrier integrity and inflammatory markers

• Translational Relevance:

  • Include samples from relevant patient populations (asthma, COPD, cystic fibrosis)

  • Correlate findings with clinical parameters

  • Test therapeutic interventions that could modulate MUC-19 expression

These methodological considerations address the research challenges specific to airway biology while incorporating the molecular techniques needed for comprehensive MUC-19 characterization in inflammatory conditions .

How should I analyze dose-response data when testing compounds that affect MUC-19 expression?

When analyzing dose-response data for compounds affecting MUC-19 expression, follow these methodological guidelines:

• Curve Fitting and Parameter Extraction:

  • Fit data to appropriate models (four-parameter logistic, Hill equation)

  • Calculate both EC50 (50% effective concentration) and EC90 (90% effective concentration) values

  • Include 95% confidence intervals for all parameters to measure uncertainty

  • Compare relative potency between compounds using fold-difference calculations

• Visualization Approaches:

  • Plot complete concentration dose-response curves rather than simplified heat maps

  • Use semi-logarithmic scale for concentration axis

  • Include all data points alongside fitted curves

  • Create comparative plots showing multiple compounds or conditions on single graphs

• Statistical Considerations:

  • Perform replicate experiments (minimum n=3) for robust statistics

  • Apply appropriate statistical tests when comparing EC50/EC90 values between groups

  • Consider non-parametric methods for non-normally distributed data

  • Account for inter-experimental variability through mixed-effects modeling

• Interpretation Guidelines:

  • Assess both potency (EC50) and efficacy (maximum effect)

  • Consider biological relevance: For biological activity, EC90 is often more relevant than EC50, especially for inhibitory compounds

  • Evaluate fold-changes relative to controls rather than absolute values alone

  • Integrate dose-response data with other experimental outcomes (e.g., functional measurements)

What statistical approaches are most appropriate for analyzing MUC-19 expression data across multiple experimental conditions?

For analyzing MUC-19 expression data across multiple experimental conditions, implement these statistical approaches:

• Experimental Design Considerations:

  • Use multifactor Design of Experiments (DOE) approach for comprehensive analysis

  • Include appropriate biological and technical replicates (minimum n=3 for each condition)

  • Incorporate nested designs when working with multiple biological sources

• Preprocessing and Quality Control:

  • Assess data distribution and transform if necessary (log transformation for non-normal data)

  • Identify and handle outliers using standardized statistical methods

  • Normalize to appropriate reference genes or total protein when comparing across samples

• Statistical Testing Framework:

  Analysis Scenario	Recommended Method	Application
  Two-group comparison	t-test or Mann-Whitney	Simple control vs. treatment
  Multiple groups	ANOVA with post-hoc tests	Comparing several conditions
  Multiple factors	Factorial ANOVA or mixed models	Complex experimental designs
  Repeated measures	RM-ANOVA or mixed effects models	Time-course experiments
  Dose-response	Non-linear regression	Concentration effects

• Advanced Statistical Methods:

  • Apply multivariate analysis for complex datasets (PCA, clustering)

  • Use multiple comparison corrections for hypothesis testing (Bonferroni, FDR)

  • Implement power analysis to determine adequate sample sizes

  • Consider Bayesian approaches for small sample sizes

• Visualization and Reporting:

  • Present data with appropriate error bars (standard deviation, standard error, or 95% CI)

  • Use data visualization techniques that accurately represent statistical significance

  • Report effect sizes alongside p-values

  • Document all statistical methods in detail for reproducibility

This comprehensive statistical framework has been shown to significantly improve research efficiency, reducing experimental timelines from months to weeks while maintaining or enhancing statistical rigor .

How can I integrate MUC-19 antibody techniques with advanced imaging methods for spatial expression analysis?

To integrate MUC-19 antibody techniques with advanced imaging methods for spatial expression analysis, implement these methodological approaches:

• Multiplex Immunofluorescence Optimization:

  • Test antibody compatibility with multiplex protocols

  • Establish optimal antibody concentration (typically start with 15 μg/mL for MUC-19)

  • Determine appropriate fluorophore combinations to minimize spectral overlap

  • Validate signal specificity with appropriate controls in multiplex context

• Advanced Microscopy Techniques:

  • Confocal microscopy for subcellular localization

  • Super-resolution microscopy (STED, STORM, PALM) for nanoscale distribution

  • Light-sheet microscopy for 3D tissue analysis

  • Live-cell imaging for dynamic mucin secretion studies

• Sample Preparation Optimization:

  • Develop clearing techniques compatible with mucin preservation

  • Optimize fixation protocols to maintain epitope accessibility

  • Establish antigen retrieval methods specific for thick tissue sections

  • Create standardized protocols for tissue orientation and sectioning

• Quantitative Image Analysis:

  • Implement automated segmentation algorithms for mucin-producing cells

  • Develop colocalization analysis with cell-type specific markers

  • Establish intensity calibration standards for quantitative comparisons

  • Create spatial distribution maps of MUC-19 expression within tissue architecture

• Integration with Molecular Data:

  • Combine with in situ hybridization for simultaneous mRNA detection

  • Correlate spatial protein expression with spatial transcriptomics data

  • Develop computational pipelines to integrate imaging with other -omics data

This methodological framework enables comprehensive spatial characterization of MUC-19 expression patterns while maintaining the high specificity demonstrated in standard immunohistochemical applications .

What approaches can I use to study post-translational modifications of MUC-19 and their functional significance?

To study post-translational modifications (PTMs) of MUC-19 and their functional significance, implement these methodological approaches:

• PTM Identification Strategies:

  • Mass spectrometry-based proteomics (enrichment for specific PTMs)

  • Site-specific antibodies for common modifications (glycosylation, phosphorylation)

  • Lectin-based detection methods for glycosylation patterns

  • Chemical labeling approaches for specific modifications

• Functional Analysis Methods:

  • Site-directed mutagenesis of modified residues

  • Expression of wildtype vs. PTM-deficient constructs

  • Pharmacological inhibitors of specific modification enzymes

  • Glycosidase treatments to remove specific glycan structures

• Experimental Design Considerations:

  • Compare normal vs. disease states for differential PTM patterns

  • Analyze PTM changes in response to inflammatory stimuli (TNF-alpha, IL-1 beta)

  • Examine tissue-specific PTM variations across expression sites

  • Design time-course experiments to track dynamic modifications

• Technical Challenges and Solutions:

  Challenge	Methodological Solution
  High molecular weight	Specialized extraction protocols, gradient gels
  Extensive glycosylation	Sequential enzymatic deglycosylation, specialized MS approaches
  Heterogeneous modifications	Single-molecule techniques, PTM-specific enrichment
  Limited antibody specificity	Multiple detection methods, validation with recombinant controls

• Data Integration Framework:

  • Correlate PTMs with protein function (secretion, viscosity, binding properties)

  • Map modifications to protein structural domains

  • Create predictive models of PTM impact on protein-protein interactions

  • Develop databases of condition-specific PTM landscapes

This comprehensive framework addresses the unique challenges of studying heavily modified mucin proteins while implementing cutting-edge techniques for PTM analysis and functional characterization.